<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303836</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02684</org_study_id>
    <secondary_id>P6574</secondary_id>
    <secondary_id>NCI-06-C-0028</secondary_id>
    <secondary_id>CDR0000459683</secondary_id>
    <secondary_id>NCI-7547</secondary_id>
    <secondary_id>NCI-P6574</secondary_id>
    <nct_id>NCT00303836</nct_id>
    <nct_alias>NCT00255203</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>A Phase II Study Using a Peptide Vaccine With or Without Aldesleukin Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase II trial is studying how well giving vaccine therapy with or without
      interleukin-2 after chemotherapy and an autologous white blood cell infusion works in
      treating patients with metastatic melanoma. Vaccines made from peptides may help the body
      build an effective immune response to kill tumor cells. Giving vaccine therapy with
      interleukin-2, chemotherapy, and an autologous white blood cell infusion may be a more
      effective treatment for metastatic melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the ability of gp100 and MART-1 peptide vaccines with or without a high-dose
      interleukin-2 (IL-2), when administered after a nonmyeloablative, lymphodepleting preparative
      regimen and reinfusion of autologous CD25+ T-regulatory-depleted lymphocytes, to mediate
      tumor regression in patients with metastatic melanoma.

      SECONDARY OBJECTIVES:

      I. Determine the generation of antitumor lymphocytes and the rate of repopulation of CD25+
      T-regulatory cells in patients treated with this regimen.

      II. Determine the toxicity of this treatment regimen.

      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients undergo apheresis and in-vitro depletion of T-regulatory cells. Patients then
      receive a nonmyeloablative, lymphocyte-depleting preparative regimen comprising
      cyclophosphamide IV over 1 hour on days -8 and -7 and fludarabine IV over 15-30 minutes on
      days -6 to -2 followed by autologous T-regulatory-depleted lymphocytes IV over 20-30 minutes
      on day 0. Patients receive vaccination with gp100:209-217 (210M) and MART-1:27-35 peptides
      emulsified in Montanide ISA-51 subcutaneously (SC) on days 0-3, 20-23, 41-44, and 62-65.
      Patients also receive filgrastim (G-CSF) SC beginning on day 1 and continuing until blood
      counts recover.

      ARM II: Patients receive treatment as in arm I. Patients also receive high-dose IL-2 IV over
      15 minutes every 8 hours on days 0-4, beginning after the lymphocyte infusion. IL-2 treatment
      repeats every 3 weeks for up to 4 courses in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed every 1-3 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2005</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective clinical response (CR or PR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-tumor T cells</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery of regulatory T cells</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of DLTs and SAEs graded according to CTCAE version 3.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo apheresis and in-vitro depletion of T-regulatory cells. Patients then receive a nonmyeloablative, lymphocyte-depleting preparative regimen comprising cyclophosphamide IV over 1 hour on days -8 and -7 and fludarabine IV over 15-30 minutes on days -6 to -2 followed by autologous T-regulatory-depleted lymphocytes IV over 20-30 minutes on day 0. Patients receive vaccination with gp100:209-217 (210M) and MART-1:27-35 peptides emulsified in Montanide ISA-51 subcutaneously (SC) on days 0-3, 20-23, 41-44, and 62-65. Patients also receive filgrastim (G-CSF) SC beginning on day 1 and continuing until blood counts recover.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment as in arm I. Patients also receive high-dose IL-2 IV over 15 minutes every 8 hours on days 0-4, beginning after the lymphocyte infusion. IL-2 treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>AL</other_name>
    <other_name>Autologous Lymphocytes</other_name>
    <other_name>autologous T cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo in vitro-treated peripheral blood stem cell transplantation</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>in vitro-treated PBPC transplantation</other_name>
    <other_name>in vitro-treated PBSC</other_name>
    <other_name>in vitro-treated peripheral blood progenitor cell transplantation</other_name>
    <other_name>PBPC transplantation, in vitro-treated</other_name>
    <other_name>peripheral blood progenitor cell transplantation, in vitro-treated</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>gp100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Antigen LB39-AA</other_name>
    <other_name>Antigen SK29-AA</other_name>
    <other_name>MART-1</other_name>
    <other_name>MART-1 Tumor Antigen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>IFA</other_name>
    <other_name>ISA-51</other_name>
    <other_name>Montanide ISA 51</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of metastatic melanoma

               -  No tumor reactive cells available for cell transfer therapy

          -  Measurable disease

          -  Previously treated with interleukin-2 (IL-2) and meets 1 of the following criteria:

               -  No response (progressive disease)

               -  Recurrent disease

          -  HLA*0201 positive

          -  ECOG performance status 0 or 1

          -  Absolute neutrophil count &gt; 1,000/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Hemoglobin &gt; 8.0 g/dL

          -  ALT and AST &lt; 3 times upper limit of normal

          -  Bilirubin ≤ 2.0 mg/dL (&lt; 3.0 mg/dL if Gilbert's disease is present)

          -  Creatinine ≤ 2.0 mg/dL

          -  Life expectancy ≥ 3 months

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for up to 4 months after
             receiving the preparative regimen

          -  No active systemic infections, coagulation disorders, or other major medical illnesses
             of the cardiovascular, respiratory, or immune system, as evidenced by a positive
             stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, or
             obstructive or restrictive pulmonary disease

          -  No autoimmune disease (e.g., autoimmune colitis or Crohn's disease) or primary
             immunodeficiency disease

          -  No HIV positivity

          -  No hepatitis B or C virus positivity

          -  No Epstein-Barr virus negativity

          -  Eligible to receive high-dose IL-2, as evidenced by the following:

               -  Patients ≥ 50 years of age must have a normal cardiac stress test (e.g., stress
                  thallium, stress MUGA, dobutamine echocardiogram, or other stress test) AND LVEF
                  ≥ 45%

               -  Patients with a history of EKG abnormalities, symptoms of cardiac ischemia, or
                  arrhythmias must have a normal cardiac stress test AND LVEF ≥ 45%

               -  Patients with a prolonged history of cigarette smoking or symptoms of respiratory
                  dysfunction must have a normal pulmonary function test, as evidenced by FEV 1 ≥
                  60% of predicted

          -  At least 4 weeks since prior systemic therapy

          -  At least 6 weeks since prior nitrosourea therapy

          -  No concurrent systemic steroid therapy

          -  Recovered immune competence after prior chemotherapy or radiotherapy

          -  No prior gp100:209-217 or MART-1:27-35 peptide vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Rosenberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute Surgery Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>June 5, 2013</last_update_submitted>
  <last_update_submitted_qc>June 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

